INDIANAPOLIS–An Eli Lilly executive has been accused by employees at its manufacturing plant in Branchburg, New Jersey of altering documents to downplay quality control issues. A second issue was being investigated at an Indianapolis facility that bottles the company’s COVID-19 treatment.
The investigations by the FDA in Indianapolis were reported by Reuters news agency.
Reports by the Food and Drug Administration indicated concerns about sanitation and quality control.
The company tells WIBC that they are bound by rules of confidentiality and that out of respect for their employees, they are not discussing specific details about any one employee.
“We take all reports of improper or inappropriate conduct seriously and we conduct thorough investigations to determine the facts. I can confirm that we received an anonymous complaint submitted through our system in April,” said spokesperson Kathryn H. Beiser.
“Lilly had already hired an external party to investigate the allegations in that complaint and this investigation is still ongoing. Depending on the outcome of that investigation, Lilly will take appropriate action. Lilly has long-standing policies and procedures designed to enable―and encourage―individuals to come forward with information about any potential issues or concerns without fear of retaliation. “
Lilly confirmed that they had submitted a response to the FDA’s report on the Indy facility, but did not discuss specifics about their response.
